Atropine sulfate 10 mg/mL Solution/ Drops
Other active recalls for Atropine Sulfate (different manufacturers) — 2 · tap to view
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Anticholinergic class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Ophthalmic atropine is used before eye examinations to dilate (open) the pupil, the black part of the eye through which you see. It is also used to relieve pain caused by swelling and inflammation of the eye.
Read the full MedlinePlus article ↗- Atropine works by blocking a nerve signal that, when overactive, can cause a dangerously slow heart rate, flooding secretions, or — in poisoning — life-threatening over-stimulation...
- Why am I being given atropine — what does it actually do?
- It's very common to notice a dry mouth, blurred vision, light sensitivity, a faster heartbeat, flushing, or difficulty urinating — those are expected effects of how atropine works...
- What side effects should I expect, and which ones mean I need to call for help?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Atropine Sulfate — tap one for details:
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII F5UM2KM3W7
Benzalkonium chloride is a chemical compound that works as a preservative and antimicrobial agent in medications. It prevents bacterial and fungal growth in liquid formulations to keep the product safe during storage and use.
-
UNII MP1J8420LU
A salt derived from edetic acid that binds to trace metals in medicines. It serves as a chelating agent and preservative to prevent metal-catalyzed breakdown of the drug and extend shelf life.
-
UNII QTT17582CB
A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
-
UNII 55X04QC32I
A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
-
UNII 70WT22SF4B
A mineral salt that acts as a buffer to maintain the pH balance of the medication. It helps stabilize the drug's potency and prevents unwanted chemical changes during storage.
-
UNII 593YOG76RN
A salt made from sodium and phosphate that helps regulate acidity and maintain proper pH balance in the medicine. It also acts as a buffer to keep the product stable.
6 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $5.540 | $27.70 / 5 ml |
| Medicaid paysCMS SDUD · 12 mo | $7.74 | $38.72 / 5 ml |
| Medicare drug plans payPart D · Q2 2026 | $7.91 | $39.53 / 5 ml |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Atropine 10 mg/mL 60219-1750-08 | Amneal | 1 bottle | $3.916 | AT1 | Availability likely | save 29% |
| Atropine sulfate 10 mg/mL 70069-0583-01 | Somerset | 1 bottle | $3.916 | AT1 | Availability likely | save 29% |
| Atropine Sulfate 10 mg/mL 70756-0653-35 | Lifestar | 1 bottle | $3.916 | AT1 | Availability likely | save 29% |
| Atropine 10 mg/mL 60219-1749-03 | Amneal | 1 bottle | $5.540 | AT1 | Availability likely | — |
| Atropine sulfate 10 mg/mLthis 70069-0582-01 | Somerset | 1 bottle | $5.540 | AT1 | Availability likely | — |
| Atropine Sulfate 10 mg/mL 70756-0652-25 | Lifestar | 1 bottle | $5.540 | AT1 | Availability likely | — |
| Isopto Atropine 10 mg/mL 00065-0303-55 | Alcon | 1 bottle | $9.701 | AT2 | Discontinued | +75% |
| atropine sulfate 10 mg/mL 00065-0817-01 | Alcon | 1 bottle | $11.605 | AT2 | Availability likely | +109% |
| Atropine Sulfate 10 mg/mL 70069-0716-01 | Somerset | 1 bottle | $11.605 | AT2 | Availability likely | +109% |
| Atropine sulfate 10 mg/mL 42799-0826-01 | Edenbridge | 1 bottle | $12.878 | AT1 | Availability likely | +132% |
| Atropine 10 mg/mL 60219-1748-02 | Amneal | 1 bottle | $12.878 | AT1 | Availability likely | +132% |
| Atropine 10 mg/mL 60505-6226-00 | Apotex | 1 bottle | $12.878 | AT1 | Availability likely | +132% |
| Atropine sulfate 10 mg/mL 70069-0581-01 | Somerset | 1 bottle | $12.878 | AT1 | Availability likely | +132% |
| Atropine Sulfate 10 mg/mL 70756-0651-25 | Lifestar | 1 bottle | $12.878 | AT1 | Availability likely | +132% |
| Atropine Sulfate 10 mg/mL 72603-0264-01 | NorthStar | 1 bottle | $12.878 | AT1 | Availability likely | +132% |
| Atropine Sulfate 10 mg/mL 24208-0965-01 | Bausch | 10 vials | — | — | FDA listed | — |
| Atropine 10 mg/mL 50090-7000-00 | A-S | 1 bottle | — | AT1 | FDA listed | — |
| Atropine 10 mg/mL 50090-7313-00 | A-S | 1 bottle | — | AT1 | FDA listed | — |
| Atropine Sulfate 10 mg/mL 67296-2124-05 | Redpharm | 1 bottle | — | AT1 | FDA listed | — |
| Atropine 10 mg/mL 67296-2200-05 | Redpharm | 1 bottle | — | AT1 | FDA listed | — |
| Atropine Sulfate 10 mg/mL 82260-0001-01 | Bausch | 10 vials | — | — | FDA listed | — |
| Atropine 10 mg/mL 68083-0671-01 | Gland | 1 bottle | — | AT1 | FDA listed | — |
| Atropine 10 mg/mL 68083-0669-01 | Gland | 1 bottle | — | AT1 | FDA listed | — |
| Atropine 10 mg/mL 68083-0670-01 | Gland | 1 bottle | — | AT1 | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🗺️ Medicaid utilization & spend
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 70069-0582-01 You're viewing this | 1 BOTTLE in 1 CARTON (70069-582-01) / 5 mL in 1 BOTTLE | 2024-07-04 | Active |
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE Atropine sulfate ophthalmic solution, 1% is indicated for: Atropine is an anti-muscarinic agent indicated for: Cycloplegia (1.1) Mydriasis (1.2) Penalization of the healthy eye in the treatment of amblyopia (1.3)
1.1 Cycloplegia
1.2 Mydriasis
1.3 Penalization of the healthy eye in the treatment of amblyopia
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION In individuals from three (3) months of age or greater, 1 drop topically to the cul-de-sac of the conjunctiva, forty minutes prior to the intended maximal dilation time. In individuals 3 years of age or greater, doses may be repeated up to twice daily as needed. In individuals from three (3) months of age or greater, 1 drop topically to the cul-de-sac of the conjunctiva, forty minutes prior to the intended maximal dilation time (2) In individuals 3 years of age or greater, doses may be repeated up to twice daily as needed.
(2)
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Atropine sulfate ophthalmic solution, USP 1%: each mL contains 10 mg of atropine sulfate equivalent to 8.3 mg of atropine. 1% ophthalmic solution (3)
⛔ Contraindications ▾
4 CONTRAINDICATIONS Hypersensitivity or allergic reaction to any ingredient in formulation (4.1)
4.1Hypersensitivity to any Component of this Medication Atropine sulfate ophthalmic solution should not be used in anyone who has demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation because it may recur.
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Photophobia and blurred vision due to pupil unresponsiveness and cycloplegia may last up to 2 weeks. (5.1) Risk of blood pressure increase from systemic absorption (5.2)
5.1Photophobia and Blurred Vision Photophobia and blurred vision due to pupil unresponsiveness and cycloplegia may last up to 2 weeks.
5.2Elevation of Blood Pressure Elevation in blood pressure from systemic absorption has been reported following conjunctival instillation of recommended doses of atropine sulfate ophthalmic solution, 1%.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling: Photophobia and Blurred Vision [See Warnings and Precautions (5.1)] Elevation in Blood Pressure [See Warnings and Precautions (5.2)] The following adverse reactions have been identified following use of atropine sulfate ophthalmic solution. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Most common adverse reactions that have been reported are eye pain and stinging on administration, blurred vision, photophobia, decreased lacrimation, increased heart rate and blood pressure (6) To report SUSPECTED ADVERSE REACTIONS, contact Somerset Therapeutics, LLC at 1-800-417-9175 or the FDA at 1-800-FDA-1088 or www.fda.gov/ medwatch.
6.1Ocular Adverse Reactions Eye pain and stinging occurs upon instillation of atropine sulfate ophthalmic solution. Other commonly occurring adverse reactions include, blurred vision, photophobia, superficial keratitis and decreased lacrimation. Allergic reactions such as papillary conjunctivitis, contact dermatitis, and lid edema may also occur less commonly.
6.2Systemic Adverse Reactions Systemic effects of atropine are related to its anti-muscarinic activity. Systemic adverse events reported include dryness of skin, mouth, and throat from decreased secretions from mucus membranes; restlessness, irritability or delirium from stimulation of the central nervous system; tachycardia; flushed skin of the face and neck.
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS The use of atropine and monoamine oxidase inhibitors (MAOI) is generally not recommended because of the potential to precipitate hypertensive crisis. (7)
7.1Monoamine oxidase inhibitors (MAOI) The use of atropine and monoamine oxidase inhibitors (MAOI) is generally not recommended because of the potential to precipitate hypertensive crisis.
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS Should only be used in pregnant women if clearly needed (8)
8.1Pregnancy Pregnancy Category C: There are no adequate and well-controlled studies of atropine sulfate in pregnant women. Animal development and reproduction studies have not been conducted with atropine sulfate. Since it is not known whether topically administered atropine sulfate can cause fetal harm, atropine sulfate ophthalmic solution, 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.
8.3Nursing Mothers Traces of atropine have been found in human milk following administration of atropine solution for injection. Because some systemic absorption occurs from topical administration, caution should be exercised when atropine sulfate ophthalmic solution, 1% is administered to a nursing woman.
8.4Pediatric Use Due to the potential for systemic absorption of atropine sulfate ophthalmic solution, the use of atropine sulfate ophthalmic solution, 1% in children under the age of 3 months is not recommended and the use in children under 3 years of age should be limited to no more than one drop per eye per day.
8.5Geriatric Use No overall differences in safety and effectiveness have been observed between elderly and younger adult patients.
🆘 Overdosage ▾
10 OVERDOSAGE In the event of accidental ingestion or toxic overdosage with atropine sulfate ophthalmic solution, supportive care may include a short acting barbiturate or diazepam as needed to control marked excitement and convulsions. Large doses for sedation should be avoided because central depressant action may coincide with the depression occurring late in atropine poisoning. Central stimulants are not recommended.
Physostigmine, given by slow intravenous injection of 1 to 4 mg (0.5 to 1 mg in pediatric populations), rapidly abolishes delirium and coma caused by large doses of atropine. Since physostigmine is rapidly destroyed, the patient may again lapse into coma after one to two hours, and repeated doses may be required. Artificial respiration with oxygen may be necessary.
Cooling measures may be needed to help to reduce fever, especially in pediatric populations. The fatal adult dose of atropine is not known. In pediatric populations, 10 mg or less may be fatal.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action Atropine is a reversible antagonist of muscarine-like actions of acetyl-choline and is therefore classified as an antimuscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically.
Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors. The pupillary constrictor muscle depends on muscarinic cholinoceptor activation. This activation is blocked by topical atropine resulting in unopposed sympathetic dilator activity and mydriasis.
Atropine also weakens the contraction of the ciliary muscle, or cycloplegia. Cycloplegia results in loss of the ability to accommodate such that the eye cannot focus for near vision.
12.2Pharmacodynamics The onset of action after administration of atropine sulfate ophthalmic solution, 1%, is usually within 40 minutes with maximal effect being reached in about 2 hours. The effect can last for up to 2 weeks in a normal eye.
12.3Pharmacokinetics The bioavailability of atropine sulfate ophthalmic solution, 1% was assessed in six healthy subjects, 24 to 29 years of age. Subjects received either 0.3 mg atropine sulfate administered as bolus intravenous injection or 0.3 mg administered as 30 μl instilled unilaterally in the cul-de-sac of the eye. Plasma l-hyoscyamine concentrations were determined over selected intervals up to eight hours after dose administration.
The mean bioavailability of topically applied atropine was 63.5 ± 29% (range 19 to 95%) with large inter-individual differences. Mean maximum observed plasma concentration for the ophthalmic solution was 288 ± 73 pg/mL. Maximum concentration was reached in 28 ± 27 min after administration.
Terminal half-life of l-hyoscamine was not affected by route of administration and was calculated to be 3 ± 1.2 hours (intravenous) and 2.5 ± 0.8 hours (topical ophthalmic). In another placebo-controlled study, the systemic exposure to l-hyoscyamine, and the anti-cholinergic effects of atropine were investigated in eight ocular surgery patients 56 to 66 years of age, following single topical ocular 0.4 mg atropine dose (given as 40 microliters of atropine sulfate ophthalmic solution, 1%). The mean (± standard deviation (SD)) C max of l-hyoscyamine in these patients was 860 ± 402 pg/mL, achieved within 8 minutes of eyedrop instillation.
Following intravenous administration, the mean (± SD) elimination half-life (t 1/2 ) of atropine was reported to be longer in pediatric subjects under 2 years (6.9 ± 3.3 hours) and in geriatric patients 65 to 75 years (10.0 ± 7.3 hours), compared to in children over 2 years (2.5 ± 1.2 hours) and in adults 16 to 58 years (3.0 ± 0.9 hours). (see
8.4Pediatric Use). Atropine is destroyed by enzymatic hydrolysis, particularly in the liver; from 13 to 50% is excreted unchanged in the urine. Traces are found in various secretions, including milk.
The major metabolites of atropine are noratropine, atropin-n-oxide, tropine, and tropic acid. Atropine readily crosses the placental barrier and enters the fetal circulation, but is not found in amniotic fluid. Atropine binds poorly (about 44%) to plasma protein, mainly to alpha-1 acid glycoprotein; age has no effect on the serum protein binding of atropine.
Atropine binding to α-1 acid glycoprotein was concentration dependent (2 to 20 mcg/mL) and nonlinear in vitro and in vivo . There is no gender effect on the pharmacokinetics of atropine administered by injection.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING Atropine sulfate ophthalmic solution, USP 1% is supplied in a white bottle, plugged with nozzle and capped with red screw cap in the following sizes: NDC 70069-581-01 2 mL fill in a 5 mL capacity bottle NDC 70069-582-01 5 mL fill in a 5 mL capacity bottle NDC 70069-583-01 15 mL fill in a 15 mL capacity bottle Storage: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Keep tightly closed.
📋 Description ▾
11 DESCRIPTION Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anticholinergic for ophthalmic use. The active ingredient is represented by the chemical structure: Chemical Name : Benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl-8-azabicyclo[3.2.1.]oct-3-yl ester, endo –(±)-, sulfate (2:1) (salt), monohydrate. Molecular Formula: (C 17 H 23 NO 3 ) 2 • H 2 SO 4 • H 2 O Molecular Weight: 694.83 g/mol Each mL Contains: Active: Atropine sulfate, 10 mg (1%) equivalent to 8.3 mg of atropine.
Inactives: benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate heptahydrate, edetate disodium dihydrate, hypromellose (2910), monobasic sodium phosphate monohydrate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6. 0), and water for injection USP. Image
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Advise patients not to touch the dropper tip to any surface as this may contaminate the solution. Advise patients that drops will sting upon instillation and advise patients that they will experience sensitivity to light and blurred vision which may last for a couple of weeks. Manufactured for: Somerset Therapeutics, LLC Somerset, NJ 08873 Made in India Code No.: KR/DRUGS/KTK/28/289/97 1201203 ST-ATS/P/01